PDCD1 and renal cell carcinoma: Furthermore, predictive capacity of TEXscore exceeded that of the CD8 + T effector, and T cell-inflamed GEP in anti-PD-1 (nivolumab) immunotherapy in renal cell carcinoma (GSE67501) (Additional file 4: Figure S4E–F).